|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
A Phase 2, Randomized, Double blind, Controlled Study to Evaluate the Safety and Efficacy of VX 440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis - VX15-440-101 / ELEVATE CF<br>
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis
A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del).
100 Clinical Results associated with Ion channels x CFTR
100 Translational Medicine associated with Ion channels x CFTR
0 Patents (Medical) associated with Ion channels x CFTR